02:40 AM EDT, 08/20/2026 (MT Newswires) -- BioPharma Credit (BPCP.L, BPCR.L) completed the sale of its indirect interest in Colombian third-party diagnostic products distributor Lumira SAS. Completion took place on Aug. 14, wrapping up the London-listed specialist life sciences debt investment trust's $419 million investment in the LumiraDx group, according to a Thursday filing. The holding company for the interest will undergo winding up following the sale. BioPharma Credit said the latest transaction and previous LumiraDx-linked disposals delivered a 101% recovery rate on the principal investment, based on gross and net.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.